Deciphera Pharmaceuticals (NASDAQ:DCPH) had its price target reduced by investment analysts at Barclays from $85.00 to $70.00 in a research note issued to investors on Wednesday, Benzinga reports.
https://www.marketbeat.com/instant-alerts/nasdaq-dcph-a-buy-or-sell-right-now-2021-02/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.